Affordable Access

deepdyve-link
Publisher Website

The effect of serum lipid levels on peripheral blood hematopoietic stem cell levels.

Authors
  • Yildirim Simsir, Ilgin1
  • Donmez, Ayhan2
  • Kabaroglu, Ceyda3
  • Yavasoglu, Irfan4
  • Basol, Gunes3
  • Gungor, Ayşe2
  • Comert Ozkan, Melda2
  • Saygili, Fusun5
  • Bolaman, Zahit4
  • Tombuloglu, Murat2
  • 1 Ege University Medical Faculty, Division of Endocrinology and Metabolism Disorders, Izmir, 35100, Turkey. Electronic address: [email protected] , (Turkey)
  • 2 Ege University Medical Faculty, Division of Hematology, Izmir, Turkey. , (Turkey)
  • 3 Ege University Medical Faculty, Division of Clinical Biochemistry, Izmir, Turkey. , (Turkey)
  • 4 Adnan Menderes University Medical Faculty, Division of Hematology, Aydin, Turkey. , (Turkey)
  • 5 Ege University Medical Faculty, Division of Endocrinology and Metabolism Disorders, Izmir, 35100, Turkey. , (Turkey)
Type
Published Article
Journal
Transfusion and Apheresis Science
Publisher
Elsevier
Publication Date
Feb 03, 2021
Pages
103074–103074
Identifiers
DOI: 10.1016/j.transci.2021.103074
PMID: 33574011
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

There are limited numbers of available retrospective studies on various hematological diseases treated with stem cell mobilization therapy. In the present study, we aimed to demonstrate the effects of serum lipid levels on peripheral blood CD34+ (PBCD34+) cell counts as well as the changes in serum lipid levels during stem cell mobilization process. PBCD34+ cell counts were compared between hypercholesterolemic patients and healthy individuals. Additionally, total cholesterol (TChol), LDL-cholesterol (LDL-C), HDL-cholesterol (HDL-C), and triglyceride (TG) levels were measured from healthy donors who underwent stem cell mobilization, at different time points (prior to filgrastim [phase 1], prior to apheresis [phase II], and the first week following apheresis [phase III]. In the hypercholesterolemia group, the PBCD34+ cell count was found to be higher among patients with elevated LDL-C (2.6 ± 0.35/μL vs. 1.7 ± 0.17/μL, p = 0.003) and TChol (2.6 ± 0.34/μL vs. 1.7 ± 0.14/μL, p = 0.006) in comparison to the healthy controls. In the mobilization group, phase II HDL-C levels (35.3 ± 2.8 mg/dL) were found to be lower than both phase I (45.6 ± 2.1 mg/dL) and phase III (44.5 ± 2.6 mg/dL) (p = 0.007). Phase II TChol levels (183.5 ± 10.0 mg/dL) were lower than both phase I (216.8 ± 8.5 mg/dL) and phase III (212.2 ± 8.4 mg/dL) (p = 0.02). At phase II, there was an inverse correlation between PBCD34+ cell count and HDL-C (r = - 0.57, p = 0.003). Our results indicate that, while increased LDL-C level is the determinant of baseline PBCD34+ cell count, reduced HDL-C is the determinant of PBCD34+ cell count during mobilization process. Copyright © 2021 Elsevier Ltd. All rights reserved.

Report this publication

Statistics

Seen <100 times